BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 2891995)

  • 1. Difluoromethylornithine for arseno-resistant Trypanosoma brucei gambiense sleeping sickness.
    Pepin J; Milord F; Guern C; Schechter PJ
    Lancet; 1987 Dec; 2(8573):1431-3. PubMed ID: 2891995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and toxicity of eflornithine for treatment of Trypanosoma brucei gambiense sleeping sickness.
    Milord F; Pépin J; Loko L; Ethier L; Mpia B
    Lancet; 1992 Sep; 340(8820):652-5. PubMed ID: 1355219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A trial treatment with eflornithine of trypanosomiasis caused by Trypanosoma brucei gambiense in the Peoples Republic of the Congo].
    Eozenou P; Jannin J; Ngampo S; Carme B; Tell GP; Schechter PJ
    Med Trop (Mars); 1989; 49(2):149-54. PubMed ID: 2507863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of human late stage gambiense trypanosomiasis with alpha-difluoromethylornithine (eflornithine): efficacy and tolerance in 14 cases in Côte d'Ivoire.
    Doua F; Boa FY; Schechter PJ; Miézan TW; Diai D; Sanon SR; De Raadt P; Haegele KD; Sjoerdsma A; Konian K
    Am J Trop Med Hyg; 1987 Nov; 37(3):525-33. PubMed ID: 3120607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose nifurtimox for arseno-resistant Trypanosoma brucei gambiense sleeping sickness: an open trial in central Zaire.
    Pépin J; Milord F; Meurice F; Ethier L; Loko L; Mpia B
    Trans R Soc Trop Med Hyg; 1992; 86(3):254-6. PubMed ID: 1412646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment of sleeping disease caused by trypanosoma brucei gambiense with alpha-difluoromethylornithine (DFMO) in a rural hospital in Zaire].
    De Groof D; Bruneel H; Musumari TS; Ruppol JF
    Med Trop (Mars); 1992; 52(4):369-75. PubMed ID: 1494306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eflornithine concentrations in serum and cerebrospinal fluid of 63 patients treated for Trypanosoma brucei gambiense sleeping sickness.
    Milord F; Loko L; Ethier L; Mpia B; Pépin J
    Trans R Soc Trop Med Hyg; 1993; 87(4):473-7. PubMed ID: 8249087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A seven days course of eflornithine for relapsing Trypanosoma brucei gambiense sleeping sickness.
    Khonde N; Pépin J; Mpia B
    Trans R Soc Trop Med Hyg; 1997; 91(2):212-3. PubMed ID: 9196773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Melarsoprol versus eflornithine for treating late-stage Gambian trypanosomiasis in the Republic of the Congo.
    Balasegaram M; Harris S; Checchi F; Ghorashian S; Hamel C; Karunakara U
    Bull World Health Organ; 2006 Oct; 84(10):783-91. PubMed ID: 17128358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eflornithine is safer than melarsoprol for the treatment of second-stage Trypanosoma brucei gambiense human African trypanosomiasis.
    Chappuis F; Udayraj N; Stietenroth K; Meussen A; Bovier PA
    Clin Infect Dis; 2005 Sep; 41(5):748-51. PubMed ID: 16080099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mortality trends and risk factors in advanced stage-2 Human African Trypanosomiasis: A critical appraisal of 23 years of experience in the Democratic Republic of Congo.
    Kazumba LM; Kaka JT; Ngoyi DM; Tshala-Katumbay D
    PLoS Negl Trop Dis; 2018 Jun; 12(6):e0006504. PubMed ID: 29897919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial.
    Priotto G; Kasparian S; Mutombo W; Ngouama D; Ghorashian S; Arnold U; Ghabri S; Baudin E; Buard V; Kazadi-Kyanza S; Ilunga M; Mutangala W; Pohlig G; Schmid C; Karunakara U; Torreele E; Kande V
    Lancet; 2009 Jul; 374(9683):56-64. PubMed ID: 19559476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The use of difluoromethylornithine in congenital trypanosomiasis due to Trypanosoma brucei-gambiense].
    Pepin J; Guern C; Milord F; Ethier L; Bokelo M; Schechter PJ
    Med Trop (Mars); 1989; 49(1):83-5. PubMed ID: 2498607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eflornithine for the treatment of human African trypanosomiasis.
    Burri C; Brun R
    Parasitol Res; 2003 Jun; 90 Supp 1():S49-52. PubMed ID: 12811548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of human trypanosomiasis caused by Trypanosoma brucei gambiense using alpha-difluoromethylornithine. Results in 7 patients].
    Taelman H; Marcelis L; Sonnet J; Kazyumba G; Van den Enden E; Wery M; Schechter PJ
    Bull Soc Pathol Exot Filiales; 1988; 81(3 Pt 2):578-88. PubMed ID: 3143491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trial of prednisolone for prevention of melarsoprol-induced encephalopathy in gambiense sleeping sickness.
    Pepin J; Milord F; Guern C; Mpia B; Ethier L; Mansinsa D
    Lancet; 1989 Jun; 1(8649):1246-50. PubMed ID: 2566790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of gambiense sleeping sickness in the Sudan with oral DFMO (DL-alpha-difluoromethylornithine), an inhibitor of ornithine decarboxylase; first field trial.
    Van Nieuwenhove S; Schechter PJ; Declercq J; Boné G; Burke J; Sjoerdsma A
    Trans R Soc Trop Med Hyg; 1985; 79(5):692-8. PubMed ID: 3938090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enantiospecific reassessment of the pharmacokinetics and pharmacodynamics of oral eflornithine against late-stage Trypanosoma brucei gambiense sleeping sickness.
    Jansson-Löfmark R; Na-Bangchang K; Björkman S; Doua F; Ashton M
    Antimicrob Agents Chemother; 2015 Feb; 59(2):1299-307. PubMed ID: 25512417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. African sleeping sickness in the United States. Successful treatment with eflornithine.
    Petru AM; Azimi PH; Cummins SK; Sjoerdsma A
    Am J Dis Child; 1988 Feb; 142(2):224-8. PubMed ID: 3124603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Melarsoprol sensitivity profile of Trypanosoma brucei gambiense isolates from cured and relapsed sleeping sickness patients from the Democratic Republic of the Congo.
    Pyana Pati P; Van Reet N; Mumba Ngoyi D; Ngay Lukusa I; Karhemere Bin Shamamba S; Büscher P
    PLoS Negl Trop Dis; 2014 Oct; 8(10):e3212. PubMed ID: 25275572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.